Show simple item record

dc.contributor.authorHopwood, Penelope
dc.contributor.authorThatcher, Nick
dc.date.accessioned2010-07-21T08:58:31Z
dc.date.available2010-07-21T08:58:31Z
dc.date.issued1991-05
dc.identifier.citationCurrent status of quality of life measurement in lung cancer patients. 1991, 5 (5):159-166; discussion 166, 169, 173 Oncologyen
dc.identifier.issn0890-9091
dc.identifier.pmid1715734
dc.identifier.urihttp://hdl.handle.net/10541/108000
dc.description.abstractQuality of life in patients with inoperable lung cancer receiving palliative treatment has become an important issue. As in other types of cancer, lack of standardization of quality of life data makes comparison between trials difficult, sometimes even impossible. Much effort is being given to the development of suitable instruments to measure quality of life and strategies to incorporate these measurements into clinical trials. The authors review studies in palliative lung cancer treatment where two crucial questions are being addressed: Do patients improve in performance status and symptom relief and does treatment toxicity outweigh disease palliation?
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshClinical Trials as Topic
dc.subject.meshEvaluation Studies as Topic
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshPalliative Care
dc.subject.meshQuality of Life
dc.titleCurrent status of quality of life measurement in lung cancer patients.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, UK.en
dc.identifier.journalOncologyen
html.description.abstractQuality of life in patients with inoperable lung cancer receiving palliative treatment has become an important issue. As in other types of cancer, lack of standardization of quality of life data makes comparison between trials difficult, sometimes even impossible. Much effort is being given to the development of suitable instruments to measure quality of life and strategies to incorporate these measurements into clinical trials. The authors review studies in palliative lung cancer treatment where two crucial questions are being addressed: Do patients improve in performance status and symptom relief and does treatment toxicity outweigh disease palliation?


This item appears in the following Collection(s)

Show simple item record